Key result
An updated computational methodology efficiently identified drug-induced changes and quantitated IC50 values in line with published values for five drugs using human stem cell-derived cardiomyocytes.
Why the study?
Human induced pluripotent stem cell-derived cardiomyocytes have drug screening potential, but their usefulness is limited by electrophysiological immaturity compared with native adult human cardiomyocytes.
An updated computational methodology improves the prediction of drug effects on mature human cardiomyocytes using data from immature stem cell-derived cardiomyocytes.
Answers are grounded in this paper and cite their sources.
Enhances iPSC-cardiomyocyte drug screening fidelity; extends prior computational methods but leaves open clinical validation.
Cardiomyocytes derived from human induced pluripotent stem cells hold great potential for drug screening applications. However, their usefulness is limited by the relative immaturity of cells’ electro-physiological properties as compared to native cardiomyocytes in the adult human heart. In this work, we extend and improve on methodology to address this limitation, building on previously introduced computational procedures which predict drug effects for mature cells based on changes in optical measurements of action potentials and Ca 2+ transients made in stem cell derived cardiac microtissues. This methodology quantifies ion channel changes through the inversion of data into a mathematical model, and maps this response to a mature phenotype through the assumption of functional invariance of fundamental intracellular and membrane channels during maturation. Here we utilize an updated action potential model to represent both immature and mature cells, apply an IC50-based model of dose-dependent drug effects, and introduce a continuation-based optimization algorithm for analysis of dose escalation measurements using five drugs with known effects. The improved methodology can identify drug induced changes more efficiently, and quantitate important metrics such as IC50 in line with published values. Consequently, the updated methodology is a step towards employing computational procedures to elucidate drug effects in mature cardiomyocytes for new drugs using stem cell-derived experimental tissues.
No takes yet. Share an insight, caveat, or question.
Jæger et al. (2019) studied Drug response in cardiomyocytes. Updated computational methodology with action potential model vs. Previous computational procedures was evaluated on Quantitation of IC50 and identification of drug-induced changes. An updated computational methodology efficiently identified drug-induced changes and quantitated IC50 values in line with published values for five drugs using human stem cell-derived cardiomyocytes.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: